A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis.
A phase II open-label randomized study of dietary supplement with epigallocatechin gallate (EGCG) to improve cardiac dysfunction in patients with AL amyloidosis who do not require chemotherapy (EpiCardiAL).
An open-label, phase II study of pomalidomide and dexamethasone (PDex) for previously treated patients with AL amyloidosis.
Amiloidosi.it
Amiloidosi.it